Acorda Therapeutics Inc. (ACOR)
NASDAQ: ACOR
· Real-Time Price · USD
0.66
-0.21 (-24.14%)
At close: Apr 03, 2024, 3:59 PM
Acorda Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Ampyra Revenue | 63.94M | 103.84M | 84.56M | 98.89M | 163.16M | 459.74M |
| Ampyra Revenue Growth | -38.43% | +22.81% | -14.49% | -39.39% | -64.51% | n/a |
| License Revenue Revenue | 99K | n/a | 114.19M | 124.83M | 180.74M | 11.69M |
| License Revenue Revenue Growth | n/a | n/a | -8.53% | -30.93% | +1445.54% | n/a |
| Product Revenue | 102.42M | n/a | 14.88M | 13.14M | 11.67M | n/a |
| Product Revenue Growth | n/a | n/a | +13.29% | +12.54% | n/a | n/a |
| Royalty Revenue | 15.11M | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 28.37M | 22.21M | 23.15M | 21.82M | 22.51M | 26.25M | 23M | 30.07M | 26.94M | 28.44M | 29.62M | 32.37M | 33.97M | 32.88M | 39.94M | 38.66M | 41.11M | 41.22M | 48.7M | 50.2M | 52.73M | 36.82M | 43.57M | 44.26M | 47.6M | 39.52M | 40.74M | 49.33M | 51.7M | 58.68M | 54.37M | 53.06M | 51.78M | 52.98M | 51.06M | 52.82M | 48.77M |
| Selling, General, and Administrative Revenue Growth | +27.76% | -4.09% | +6.08% | -3.06% | -14.25% | +14.16% | -23.51% | +11.62% | -5.28% | -3.99% | -8.48% | -4.71% | +3.32% | -17.68% | +3.31% | -5.96% | -0.28% | -15.36% | -2.97% | -4.80% | +43.20% | -15.50% | -1.56% | -7.01% | +20.45% | -3.00% | -17.42% | -4.58% | -11.89% | +7.94% | +2.47% | +2.46% | -2.27% | +3.78% | -3.34% | +8.30% | n/a |
| Research and Development Revenue | 954K | 1.01M | 1.21M | 1.55M | 1.39M | 1.2M | 1.38M | 1.52M | 1.69M | 1.37M | 1.93M | 2.37M | 4.75M | 4.32M | 5.73M | 5.25M | 7.71M | 9.02M | 16.07M | 18.96M | 16.03M | 27.06M | 22.86M | 25.91M | 30.56M | 35.14M | 33.29M | 51.18M | 46.49M | 53.8M | 54.78M | 50.29M | 44.57M | 43.99M | 43.36M | 31.23M | 30.64M |
| Research and Development Revenue Growth | -5.45% | -16.40% | -22.13% | +11.83% | +15.21% | -13.02% | -9.31% | -9.98% | +24.01% | -29.26% | -18.66% | -50.01% | +9.85% | -24.54% | +9.02% | -31.80% | -14.61% | -43.86% | -15.22% | +18.29% | -40.76% | +18.39% | -11.79% | -15.22% | -13.04% | +5.58% | -34.97% | +10.09% | -13.58% | -1.79% | +8.92% | +12.84% | +1.32% | +1.46% | +38.83% | +1.94% | n/a |